Evidence map›Paper›PMID 42453168›Full record

ArticleCHEST pulmonary2026

Outcomes After Acute Respiratory Failure in Patients With Interstitial Lung Disease.

Rupali Sood, Haeun Lee, Matthew R Lammi, Erica Farrand, Karthik Suresh, Michelle Sharp, David N Hager, Sonye Danoff, Chad H Hochberg

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CHEST pulmonary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rupali SoodDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Haeun LeeDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Matthew R LammiDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Erica FarrandDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Karthik SureshDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Michelle SharpDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
David N HagerDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Sonye DanoffDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.
Chad H HochbergDivision of Pulmonary and Critical Care (R. S., M. R. L., K. S., M. S., D. N. H., S. D., and C. H. H.) and the Department of Biomedical Informatics and Data Science (H. L.), The Johns Hopkins University, Baltimore, MD; and the Division of Pulmonary and Critical Care (E. F.), University of California, San Francisco, San Francisco, CA.

Funding

Severe Acute Respiratory Failure After Immune Checkpoint Inhibitor Therapy: Risk Factors and OutcomesF32HL182250 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Rupali Sood · 2025 to 2026
$185k
NHLBI NIH HHS F32 HL182250
6 · The paper itself

Abstract

backgroundInterstitial lung diseases (ILDs) are a heterogeneous group of pulmonary disorders that can result in acute or chronic forms of respiratory failure. Prior studies have shown high mortality among patients with ILD receiving intensive care, but most have focused on idiopathic pulmonary fibrosis (IPF) and have not characterized other ILD subgroups. RESEARCH QUESTION: Does 90-day transplant-free survival differ by ILD subgroup in patients with acute respiratory failure (ARF) requiring respiratory support? STUDY DESIGN AND

methodsWe conducted a retrospective cohort study of adults with ILD admitted to 5 hospitals within our health system (2017-2024) using electronic record health data. We pragmatically defined ARF as receipt of ≥ 24 continuous hours of invasive or noninvasive respiratory support. We identified ILD diagnosis using validated International Classification of Diseases, version 10, Clinical Modification codes categorized into IPF/idiopathic interstitial pneumonia, connective tissue disease-associated ILD (CTD-ILD), exposure-related ILD, sarcoidosis, or other ILD. We evaluated 90-day transplant-free survival with multivariable Cox proportional hazards models adjusted for demographics, comorbidities, hospital type, and acute illness severity. Secondary outcomes included in-hospital death or hospice discharge and hospital length of stay.

resultsAmong 982 patients with ILD and ARF (median age, 70 years; 50% female), 269 (27%) were categorized as IPF/idiopathic interstitial pneumonia, 74 (8%) were categorized as CTD-ILD, 57 (6%) were categorized as exposure-related ILD, 171 (17%) were categorized as sarcoidosis, and 411 (42%) were categorized as other. By day 90, 466 patients (48%) had died or underwent transplant, with rates ranging from 42% in patients with CTD-ILD to 54% in exposure-related ILD. There were no significant differences in adjusted transplant-free survival or secondary outcomes overall, or when stratified by type of respiratory support.

interpretationIn this multihospital cohort of critically ill patients with ILD and ARF, 90-day transplant-free survival was poor and did not differ by ILD subgroup, even after adjustment for key confounders. These findings underscore the seriousness of ARF among patients with ILD.

Indexed as

acute respiratory failureinterstitial lung disease

Identifiers

PMID42453168
PMCPMC13367426

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.